Table 2.
Clinical characteristics for ATM, CHEK2, and HOXB13 germline mutations.
| ATM Mutation Carriers | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Age at Diagnosis | PSA 1 | Grade Group | Stage | Architecture 2 | D’Amico | Primary Treatment | Age at Death | Cause of Death | Age at Diagnosis of Other Primary Malignancy |
| 78 | 13.6 | - | - | - | Int | Radiation | 87 | PCa | - |
| 90 | 210 | 5 | T1c | No | High | Non-curative | 93 | PCa | - |
| 57 | 160 | - | - | - | High | Radiation | 75 | MDS 3 | 70, MDS |
| 65 | 20 | 5 | T1c | Cribriform | High | Radiation | - | - | 66, Renal |
| 75 | 5 | 3 | T3aN1 | Cribriform | High | Prostatectomy | - | - | |
| 68 | 12 | 5 | T3b | IDCP | High | Prostatectomy | - | - | - |
| 49 | 2.6 | 3 | T2a | IDCP, Cribriform | Int | Prostatectomy | - | - | - |
| 42 | 6.9 | 1 | - | Low | Prostatectomy | - | - | - | |
| 61 | 12 | 2 | T2c | - | High | Prostatectomy | - | - | 83, Lung, Melanoma |
| CHEK2 Mutation Carriers | |||||||||
| 80 | - | 5 | T4 | - | High | Prostatectomy | 81 | Cardiac | 78, Bladder, Colon |
| 56 | 8.8 | 2 | T2c | - | High | Prostatectomy | - | - | 47, Breast |
| HOXB13G84E Mutation Carriers | |||||||||
| 68 | 6.7 | 1 | T1c | Low | Radiation | 92 | - | 80, Breast | |
| 69 | 5.3 | 2 | T2N0 | Int | Prostatectomy | - | - | - | |
| 47 | 3.8 | 2 | T3a | High | Prostatectomy | - | - | - | |
| 64 | - | 2 | T2a | Int | - | 89 | PCa | - | |
1 PSA immediately prior to undergoing diagnostic biopsy; 2 High-risk pathology features identified within prostatic adenocarcinoma; Abbreviations: Myelodysplastic syndrome (MDS), D’Amico Intermediate-risk (Int), intraductal carcinoma of the prostate (IDCP).